Skip to main content

Market Overview

Anavex Confirms Phase 2a Trial Data Of ANAVEX 2-73 In Alzheimer's Patients Presented At AAIC


Anavex Life Sciences Corp. (NASDAQ: AVXL) confirmed positive results from the Phase 2a Alzheimer's study for ANAVEX 2-73. Two days back, it released the statement on the update about the trial.

Anavex advisor and an Alzheimer clinical trialist, Norman Relkin, said, "To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer's patients study. This was a Phase 2a study, primarily designed to determine which ANAVEX 2-73 dosages are safe to administer to mild to moderate stage Alzheimer's patients."

The company indicated the trial was successful in establishing the maximum tolerated dose apart from revealing the range of ANAVEX 2-73 doses, which were well-tolerated by Alzheimer patients. The study also offered encouraging evidence confirming the previously reported positive trends in some cognitive and biologic measures persisted over a period of approximately 31 weeks.

However, the company clarified that this analysis was based on a relatively small number of subjects receiving a variety of doses. Therefore, the company said that that these findings might not reflect the full potential ANAVEX 2-73 in treating Alzheimer's disease.

Anavex indicated a detailed pre-planned analysis of the pharmacodynamic results is in progress. The company believes that it is one of the key factors of relevance for regulatory agencies to assess the maximum dose for future studies.

At time of writing, shares of the company traded 11.75 percent higher at $3.92.


Related Articles (AVXL)

View Comments and Join the Discussion!

Posted-In: Biotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at